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Cognitive behavioural therapy for adults with dissociative 
seizures (CODES): a pragmatic, multicentre, randomised 
controlled trial
Laura H Goldstein, Emily J Robinson, John D C Mellers, Jon Stone, Alan Carson, Markus Reuber, Nick Medford, Paul McCrone, Joanna Murray, 
Mark P Richardson, Izabela Pilecka, Carole Eastwood, Michele Moore, Iris Mosweu, Iain Perdue, Sabine Landau*, Trudie Chalder*, on behalf of the 
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Summary
Background Dissociative seizures are paroxysmal events resembling epilepsy or syncope with characteristic features 
that allow them to be distinguished from other medical conditions. We aimed to compare the effectiveness of 
cognitive behavioural therapy (CBT) plus standardised medical care with standardised medical care alone for the 
reduction of dissociative seizure frequency.
Methods In this pragmatic, parallel-arm, multicentre randomised controlled trial, we initially recruited participants at 
27 neurology or epilepsy services in England, Scotland, and Wales. Adults (≥18 years) who had dissociative seizures in the 
previous 8 weeks and no epileptic seizures in the previous 12 months were subsequently randomly assigned (1:1) from 
17 liaison or neuropsychiatry services following psychiatric assessment, to receive standardised medical care or CBT plus 
standardised medical care, using a web-based system. Randomisation was stratified by neuropsychiatry or liaison 
psychiatry recruitment site. The trial manager, chief investigator, all treating clinicians, and patients were aware of 
treatment allocation, but outcome data collectors and trial statisticians were unaware of treatment allocation. Patients 
were followed up 6 months and 12 months after randomisation. The primary outcome was monthly dissociative seizure 
frequency (ie, frequency in the previous 4 weeks) assessed at 12 months. Secondary outcomes assessed at 12 months 
were: seizure severity (intensity) and bothersomeness; longest period of seizure freedom in the previous 6 months; 
complete seizure freedom in the previous 3 months; a greater than 50% reduction in seizure frequency relative to 
baseline; changes in dissociative seizures (rated by others); health-related quality of life; psychosocial functioning; 
psychiatric symptoms, psychological distress, and somatic symptom burden; and clinical impression of improvement 
and satisfaction. p values and statistical significance for outcomes were reported without correction for multiple 
comparisons as per our protocol. Primary and secondary outcomes were assessed in the intention-to-treat population 
with multiple imputation for missing observations. This trial is registered with the International Standard Randomised 
Controlled Trial registry, ISRCTN05681227, and ClinicalTrials.gov, NCT02325544.
Findings Between Jan 16, 2015, and May 31, 2017, we randomly assigned 368 patients to receive CBT plus standardised 
medical care (n=186) or standardised medical care alone (n=182); of whom 313 had primary outcome data at 12 months 
(156 [84%] of 186 patients in the CBT plus standardised medical care group and 157 [86%] of 182 patients in the 
standardised medical care group). At 12 months, no significant difference in monthly dissociative seizure frequency was 
identified between the groups (median 4 seizures [IQR 0–20] in the CBT plus standardised medical care group vs 
7 seizures [1–35] in the standardised medical care group; estimated incidence rate ratio [IRR] 0·78 [95% CI 0·56–1·09]; 
p=0·144). Dissociative seizures were rated as less bothersome in the CBT plus standardised medical care group than the 
standardised medical care group (estimated mean difference –0·53 [95% CI –0·97 to –0·08]; p=0·020). The CBT plus 
standardised medical care group had a longer period of dissociative seizure freedom in the previous 6 months (estimated 
IRR 1·64 [95% CI 1·22 to 2·20]; p=0·001), reported better health-related quality of life on the EuroQoL-5 Dimensions-5 
Level Health Today visual analogue scale (estimated mean difference 6·16 [95% CI 1·48 to 10·84]; p=0·010), less 
impairment in psychosocial functioning on the Work and Social Adjustment Scale (estimated mean difference –4·12 
[95% CI –6·35 to –1·89]; p<0·001), less overall psychological distress than the standardised medical care group on the 
Clinical Outcomes in Routine Evaluation-10 scale (estimated mean difference –1·65 [95% CI –2·96 to –0·35]; p=0·013), 
and fewer somatic symptoms on the modified Patient Health Questionnaire-15 scale (estimated mean difference –1·67 
[95% CI –2·90 to –0·44]; p=0·008). Clinical improvement at 12 months was greater in the CBT plus standardised medical 
care group than the standardised medical care alone group as reported by patients (estimated mean difference 0·66 
[95% CI 0·26 to 1·04]; p=0·001) and by clinicians (estimated mean difference 0·47 [95% CI 0·21 to 0·73]; p<0·001), and 
the CBT plus standardised medical care group had greater satisfaction with treatment than did the standardised medical 
care group (estimated mean difference 0·90 [95% CI 0·48 to 1·31]; p<0·001). No significant differences in patient-
reported seizure severity (estimated mean difference –0·11 [95% CI –0·50 to 0·29]; p=0·593) or seizure freedom in the 
last 3 months of the study (estimated odds ratio [OR] 1·77 [95% CI 0·93 to 3·37]; p=0·083) were identified between the 
groups. Furthermore, no significant differences were identified in the proportion of patients who had a more than 50% 
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Introduction
Dissociative seizures are paroxysmal episodes of altered 
awareness, resembling epileptic seizures or syncope, 
which are not explained by these or other medical 
disorders and usually have distinctive clinical features.1 
Between 12% and 20% of adults presenting in epilepsy 
clinics have dissociative seizures.2 Prevalence estimates 
range between 2 and 50 cases per 100 000 individuals;3 a 
UK-based study observed an annual inci dence of around 
4·9 cases per 100 000 individuals.4 We have adopted the 
term dissociative seizures in preference to others 
(eg, psychogenic non-epileptic seizures, non-epileptic 
attack disorder) because it is consistent with widely used 
classifications (ie, ICD-10),5 highlights that the diagnosis 
is not solely a process of exclusion, and conveys a 
mechanism that can be discussed with patients.
Around 75% of adults with dissociative seizures are 
women.6 Modal onset of dissociative seizures is between 
the late teenage years and early twenties, but dissociative 
seizures can develop at any point across the lifespan.6 
Most adults with dissociative seizures present with a 
range of comorbid psychiatric and psychological 
difficulties. Outcome is generally poor,6 quality of life is 
worse than for people with epilepsy,7 and health service 
use among individuals with dissociative seizures is high.8
The most consistent predictive factor of poor outcome for 
people with dissociative seizures seems to be the duration 
of symptoms, whereby a longer duration of the disorder is 
associated with negative outcomes.9–11 Additional factors 
that negatively predict outcomes include the receipt of state 
financial benefits,12 having previous psychiatric diagnoses,12 
and other evidence of psychopathology13 and inter personal 
difficulties.14 Employ ment,4,15 better educa tional attain-
ment and intelligence quotient,16,17 and less evidence of 
somatisation18 have been found to predict better outcome.
In the UK, no standardised care pathway exists for 
people with dissociative seizures. Although psychological 
treatment has been considered the treatment of choice, 
the availability of such treatment is variable,19 despite 
guidance20 that when dissociative seizures are suspected, 
referral should be made to psychiatric or psychological 
services for evaluation and intervention.
Psychological interventions might be associated with a 
reduction in dissociative seizures,21 although seizures 
might also remit spontaneously9 or after information 
provision.22 However, no adequately powered randomised 
controlled trials have been done to assess the use of 
psychotherapeutic treatments.23,24 A small, four-arm pilot 
randomised controlled trial in 34 patients24 evaluated 
outcome in terms of dissociative seizure frequency and a 
range of secondary outcomes following 12 sessions of 
cognitive behavioural therapy (CBT)-informed psycho-
therapy with or without flexible-dose sertraline, ser tra-
line alone, or treatment as usual. Within-group analyses 
showed that both CBT-informed psycho thotherapy 
groups had a significant reduction in disso ciative seizure 
frequency during the treatment period (CBT-informed 
psycho thotherapy (n=9) 51·4% reduction, p=0·01; CBT-
informed psychothotherapy plus sertraline (n=9) 
59·3% reduction, p=0·008) over 16 weeks, and improve-
ment in a range of secondary outcomes, including global 
functioning. No significant differences in dissociative 
seizure frequency were identified in the sertraline-alone 
group (n=9; p=0·08) or the treatment as usual group 
(n=7; p=0·19). Our 2010 proof-of-concept randomised 
controlled trial23 including 66 patients indicated that 
dissociative seizure-specific CBT plus neuro psychiatric 
care could lead to a reduction in dissociative seizure 
frequency at the end of treatment compared with neuro -
psychiatric treatment alone; however, between-group 
reduction in dissociative seizure frequency compared with baseline (OR 1·27 [95% CI 0·80 to 2·02]; p=0·313). 
Additionally, the 12-item Short Form survey–version 2 scores (estimated mean difference for the Physical Component 
Summary score 1·78 [95% CI –0·37 to 3·92]; p=0·105; estimated mean difference for the Mental Component Summary 
score 2·22 [95% CI –0·30 to 4·75]; p=0·084), the Generalised Anxiety Disorder-7 scale score (estimated mean difference 
–1·09 [95% CI –2·27 to 0·09]; p=0·069), and the Patient Health Questionnaire-9 scale depression score (estimated mean 
difference –1·10 [95% CI –2·41 to 0·21]; p=0·099) did not differ significantly between groups. Changes in dissociative 
seizures (rated by others) could not be assessed due to insufficient data. During the 12-month period, the number of 
adverse events was similar between the groups: 57 (31%) of 186 participants in the CBT plus standardised medical care 
group reported 97 adverse events and 53 (29%) of 182 participants in the standardised medical care group reported 
79 adverse events.
Interpretation CBT plus standardised medical care had no statistically significant advantage compared with 
standardised medical care alone for the reduction of monthly seizures. However, improvements were observed in a 
number of clinically relevant secondary outcomes following CBT plus standardised medical care when compared 
with standardised medical care alone. Thus, adults with dissociative seizures might benefit from the addition of 
dissociative seizure-specific CBT to specialist care from neurologists and psychiatrists. Future work is needed to 
identify patients who would benefit most from a dissociative seizure-specific CBT approach.
Funding National Institute for Health Research, Health Technology Assessment programme.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
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differences were not significant 6 months after the end 
of treatment. These findings informed the design of this 
randomised controlled trial. We aimed to assess 
the effectiveness of dissociative seizure-specific CBT in 
reducing the fre quency of dis sociative seizures and 
improving function ing com pared with standardised 
medical care after 12 months of follow-up.
Methods
Study design and participants
In this pragmatic, parallel-group, multicentre random-
ised controlled trial, we initially recruited participants 
from 27 neurology or epilepsy services in England, 
Scotland, and Wales. Eligible partici pants were adults 
(≥18 years) who had dissociative seizures in the pre-
vious 8 weeks (diagnosis preferably confirmed by 
video-electroencephalogram [EEG] or, if not available, 
clinical consensus provided by two consultants involved 
in the patient’s care or by expert review of the clinical 
records and relevant investigations by one of two neurol-
ogists in the research team), without a docu mented 
history of intellectual disabilities, who were able to 
complete seizure diaries and questionnaires, and were 
willing to have a psychiatric assessment at 3 months 
after diagnosis.25,26 Due to the uncertainty of being able 
to provide interpreters for CBT sessions, only patients 
with sufficient English proficiency to enable completion 
of therapy and questionnaires without an interpreter 
were included. Patients with comorbid epilepsy could 
only participate if they had been free of epileptic seizures 
for 12 months, and patients who met DSM-IV criteria for 
current drug or alcohol dependence were excluded. 
Research in context
Evidence before this study
For patients with dissociative seizures, the general consensus is 
that careful explanation of the diagnosis followed by 
psychotherapy is the treatment of choice, although to date, 
no standardised treatment pathways have been established 
globally. A 2014 Cochrane review highlighted the paucity of 
adequate randomised controlled trials in this field. Existing 
studies were small or did not include dissociative seizure 
occurrence as an outcome. The best evidence was considered to 
be from a 2010 pilot randomised controlled trial study, which 
evaluated the benefit of dissociative seizure-specific cognitive 
behavioural therapy (CBT) for adults with dissociative seizures 
plus standard medical (neuropsychiatric) care, compared with 
standard medical care alone. That proof-of-concept study, which 
followed on from an uncontrolled study and a single case study, 
indicated that a dissociative seizure-specific CBT package plus 
standard medical care led to a greater reduction in dissociative 
seizures at the end of treatment than did standard care alone, 
although at 6-month follow-up, the between-group difference 
was non-significant.
We searched PubMed from database inception to Oct 16, 2019, 
without language restrictions, using the search terms “([therapy 
and dissociative seizures)]” OR “([CBT and dissociative seizures])” 
OR “([therapy and psychogenic nonepileptic seizures])” OR 
“([CBT and psychogenic nonepileptic seizures])” OR “([therapy 
and PNES])” OR “([CBT and PNES])” OR “([therapy and 
nonepileptic attack disorder])” OR “([CBT and nonepileptic attack 
disorder])” OR “([therapy and NEAD])” OR “([CBT and NEAD])”. 
Our search yielded one additional underpowered pilot 
randomised controlled trial that assessed CBT-informed 
psychotherapy alone, CBT-informed psychotherapy with 
pharmacotherapy, pharmacotherapy, and treatment as usual, 
but no adequately powered multi-site effectiveness studies.
Added value of this study
Our study compared standardised medical care alone with 
dissociative seizure-specific CBT plus standardised medical 
care. Standardised medical care aimed to provide an optimised 
clinical pathway involving neurologists and psychiatrists with 
standardised communication guidelines and materials. 
Our randomised controlled trial of adults with dissociative 
seizures is the largest to date to assess a psychological 
intervention in this patient group. Although no statistically 
significant difference in dissociative seizure frequency at 
12 months was identified between the CBT plus standardised 
medical care and standardised medical care alone groups, 
significant improvements were identified for a number of 
clinically relevant secondary outcomes (highest number of 
consecutive dissociative seizure-free days in the past 6 months, 
functional status, self-rated and clinician-rated change in 
global impression scores, and satisfaction with treatment) 
among the CBT plus standardised medical care group when 
compared with the standardised medical care alone group. 
This pragmatic study shows that although dissociative seizure-
specific CBT did not result in a statistically significant reduction 
in the primary outcome of monthly dissociative seizures when 
compared with standardised medical care, the combined 
treatment approach might improve a number of relevant 
clinical outcome measures.
Implications of all the available evidence
Although no significant difference in monthly dissociative seizure 
frequency was identified between the treatment groups, 
this study expands on previous evidence suggesting that CBT 
specific to dissociative seizures might be beneficial for adults with 
dissociative seizures and demonstrates that the application of 
such an intervention does not have to be limited to highly 
specialised centres. The additional implementation of dissociative 
seizure-specific, manualised, and individualised CBT can be 
delivered by clinical psychologists or cognitive behavioural 
psychotherapists. Therapy resulted in improvements in a range of 
dissociative seizure-related and psychosocial secondary outcomes 
in the CBT plus standardised medical care group compared with 
standardised medical care alone.
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Around 3 months after enrolment and consent for the 
initial screening phase of the study was obtained, 
participants were assessed in one of 17 neuropsychiatry 
or liaison psychiatry services. The 3-month delay was 
implemented to avoid recruitment of patients whose 
dissociative seizures might remit quickly after delivery 
of a diagnosis and information provision alone22 and to 
allow time for appointments to be arranged. Participants 
who met further eligibility criteria25,26 and provided 
consent were recruited. The main approved modification 
implemented after publication of the study protocol and 
analysis plan was to extend the number of participants 
screened in the neurology and epilepsy settings 
and numbers randomly assigned to ensure adequate 
partici pants at follow-up. The study was approved by 
the London-Camberwell St Giles Research Ethics 
Committee. The study protocol and statistical analysis 
plan have been published previously.25,26 All participants 
provided separate written informed consent for the 
3-month observation period and the randomised 
controlled trial.
Randomisation and masking
Participants were randomly assigned (1:1) to standardised 
medical care or CBT plus standardised medical care, by 
either a designated researcher or the trial manager using 
a web-based system maintained by the King’s Clinical 
Trials Unit (London, UK). Randomisation was stratified 
by neuropsychiatry or liaison psychiatry recruitment site 
(randomly varying block sizes within strata). In view of 
the nature of the interventions, the trial manager, chief 
investigator, all treating clinicians, and patients were 
aware of treatment allocation, but outcome data collectors 
and trial statisticians were unaware of treatment 
allocation.
Procedures
Patients were informed of the dissociative seizures 
dia gnosis by an epilepsy specialist or neurologist using 
suggested diagnosis communication guidelines.25 
Patients were provided with a neurology trial-specific 
information booklet about dissociative seizures. After 
patient consent was obtained for the 3-month observation 
period, we collected demographic information, study 
participants were instructed in seizure diary completion, 
and seizure data were collected every 2 weeks by a 
researcher. The neurologist who had explained the 
dissociative seizures diagnosis referred the participant to 
a psychiatrist in a specified National Health Service 
(NHS) clinic for an appointment around 3 months later. 
At this appointment, the psychiatrist reviewed the 
diagnosis and discussed it with the patient using 
suggested guidelines, did a clinical psychiatric assess-
ment, provided the patient with a further psychiatry trial-
specific information booklet, and assessed the patient’s 
eligibility for the randomised controlled trial. Eligible 
patients who were willing to be contacted about the trial 
were seen by a researcher who confirmed eligibility, 
obtained consent to participate in the randomised 
controlled trial, and did baseline assessments before 
randomisation. The interven tions are described in detail 
in the appendix (pp 4–7) and have been published 
previously.25
To assess the fidelity of CBT delivery, after obtaining 
patient consent we audio-recorded therapy sessions. 
Two experienced CBT therapists who had not provided 
therapy in the trial blindly rated one session (chosen at 
random from one of two preselected sessions) from each 
of 36 therapists for whom we had usable session 
recordings (39 therapists overall). The raters evaluated 
therapists’ adherence to the treatment manual, whether 
they could be considered to be delivering CBT, the quality 
of the therapeutic alliance, and the extent to which 
dissociative seizure-specific CBT skills were used in 
sessions, on the basis of identified competencies.27 Items 
were scored on a 0–7 scale. Scores were standardised; a 
score of 100 indicated best possible performance.
All outcomes were assessed at 12 months after 
randomisation (appendix pp 8–53).26 Outcome measures 
were also obtained at baseline and at 6 months after 
randomisation to maintain participant involvement and 
inform modelling of the 12-month trial outcomes 
(appendix pp 8–53). Patients were asked to complete 
seizure diaries for each week of the study, and were 
contacted every 2 weeks for these data or, where diary 
data were not available, data were obtained from a single 
self-report question about seizures over the previous 
4 weeks. For patients randomly assigned to receive CBT, 
compliance with treatment was defined as attendance at 
nine or more CBT sessions.26
Further clinical and demographic data were collected 
at recruitment into the screening phase or imme di-
ately before randomisation: a locally devised measure 
of the patients’ level of agreement with the diagnosis 
of dissociative seizures (collected at screening); pre-
randomisation admin istration of the Mini-International 
Neuropsychiatric Interview (MINI) version 6.0;28 the Self-
report Standardised Assessment of Personality-abbre-
viated Scale (SAPAS-SR) for maladaptive personality 
traits (0=no traits, 8=all traits),29 and the Index of Multiple 
Deprivation.30–32
Outcomes
The primary outcome was monthly seizure frequency 
(ie, dissociative seizure frequency in the previous 4 weeks) 
assessed at 12 months. Construction of the primary 
outcome measure is explained in the appendix (pp 75–76).
Secondary outcomes assessed at 12 months were 
seizure severity (intensity) and bothersomeness measured 
using the Seizure Severity Scale; longest period of seizure 
freedom in the previous 6 months; the proportion of 
patients with complete seizure freedom during the final 
3 months of the study; the proportion of patients who had 
more than 50% reduction in seizure frequency relative to 
For more on the neurology trial-
specific information booklet 
see http://www.codestrial.org/
information-
booklets/4579871164
For more on the psychiatry trial-
specific information booklet 
see http://www.codestrial.org/
information-
booklets/4579871164
See Online for appendix
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901 patients diagnosed with dissociative seizures
screened for eligibility 56 excluded
 11 insufficient English for treatment with CBT or to complete questionnaires without an interpreter
 10 diagnosis of current epileptic seizures 
  8 documented history of intellectual disabilities
  7 no dissociative seizures within previous 8 weeks
  6 unable to complete seizure diaries and questionnaires
  4 not willing to complete seizure diaries regularly or have psychiatric assessment
  4 met DSM-IV criteria for current drug or alcohol dependence
  2 unable to give written informed consent
  2 currently having CBT for another disorder 
  2 previously had a CBT-based treatment for dissociative seizures at a trial-participating centre845 patients eligible for further observation
147 did not consent to observation period
 85 did not want to take part
 61 could not be contacted
 1 other
698 consented to observation period
130 did not attend psychiatry assessment
568 assessed by psychiatrist at 3 months
142 excluded
 36 no dissociative seizures in the 8 weeks before psychiatric assessment
 26 patient and clinician did not consider randomisation suitable
 15 diagnosis of current epileptic seizures and dissociative seizures
 13 not willing (or able) to continue to complete seizure diaries and questionnaires
 12 considered at imminent risk for self-harm
 10 not willing (or able) to attend weekly or fortnightly sessions if randomised to CBT
 10 current benzodiazepine use exceeding the equivalent of diazepam 10 mg per day
 8 did not provide regular seizure frequency data following receipt of dissociative seizure diagnosis
 6 currently having CBT for another disorder
 3 met DSM-IV criteria for current drug or alcohol dependence
 2 previously had a CBT-based treatment for dissociative seizures at a trial-participating centre 
 1 active psychosis
426 eligible for randomised controlled trial
58 withdrew consent or could not be contacted
368 consented to trial and randomly assigned
182 assigned to standardised medical care
1 received CBT plus standardised medical care
  in error*
25 withdrew
 15 lost to follow-up
 5 did not want to continue
  3 unknown reason
 2 other
181 received allocated treatment
182 included in ITT analysis
 157 had 12-month outcome data available
186 assigned to CBT plus standardised medical care
46 did not receive allocated treatment
30 withdrew
 23 lost to follow-up
 4 did not want to continue
 3 unknown reason
140 received allocated treatment*
186 included in ITT analysis
 156 had 12-month outcome data available
Figure 1: Trial profile
The number of standardised 
medical care sessions offered 
and attended per group, 
and the number of CBT sessions 
attended in the CBT plus 
standardised medical care 
group are presented in the 
appendix (p 68). Multiple 
imputation was used to 
facilitate an ITT analysis; 
all randomised participants 
contributed to the statistical 
analysis. CBT=cognitive 
behavioural therapy. 
ITT=intention-to-treat analysis. 
*Treatment receipt of CBT was 
defined as attendance at nine 
or more sessions (as per 
definition of compliance).
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baseline; informants’ (ie, carers or others nominated by 
patients) ratings of changes in the patients’ dissociative 
seizures; health-related quality of life (12-item Short 
Form 12 Survey–version 2 [SF-12v2] scores comprising 
Physical Component Summary and Mental Component 
Summary scores; and the EQ-5D-5L visual analogue 
scale); psychosocial fun ctioning (Work and Social 
Adjustment Scale [WSAS]); psychiatric symptoms and 
psychological distress (Generalised Anxiety Disorder-7 
scale, Patient Health Questionnaire [PHQ]-9 depression 
measure, Clinical Outcomes in Routine Evaluation-10 
[CORE-10]); somatic symptom burden (modified 
PHQ-15,33 which measured self-reported presence or 
absence of 30 symptoms [15 common symptoms 
seen in primary care, ten neurological symptoms, and 
five psychological symptoms]); and clinical impression of 
improvement (Clinical Global Impression score [rated by 
the patient and by the psychiatrist or neuro logist]) and 
satisfaction with treatment. All secondary outcomes are 
listed in the appendix (pp 8–53).25
Additionally, CBT therapists measured improvement on 
the Clinical Global Impression score for patients receiving 
CBT at the end of session 12.
The study protocol25 (appendix pp 8–53) also included a 
health economics evaluation (using the Client Service 
Receipt Inventory, EQ-5D-5L, Short-Form six-dimension 
utility index derived from the SF-12v2, and hospital 
episode statistics) and a process evaluation, which will 
be reported elsewhere. Further secondary data analyses 
to investigate mediator and moderator hypotheses 
(avoidance of people, places and situations; 12-item 
Beliefs About Emotions Scale; belief in diagnosis of 
dissociative seizures; and belief in being given the correct 
treatment)25 are planned and will be reported elsewhere.
We defined serious adverse events as any adverse event 
that resulted in death; was life-threatening; required 
hospital admission or prolongation of existing hospital 
stay; resulted in a new persistent or new significant 
disability or incapacity; was any other important medical 
condition that might jeopardise the participant and might 
require medical or surgical intervention to prevent one of 
the outcomes listed; or any new episode of deliberate self-
harm. We also recorded reports of suicidal ideation as 
serious adverse events. All adverse events and serious 
adverse events were reviewed by three independent raters. 
Adverse events were recorded for the entire 12-month 
follow-up period. Participants were specifically asked 
about illnesses and hospital admissions at the 6-month 
and 12-month follow-up timepoints, but they were also 
reported by clinicians and research workers whenever 
they became aware of them.
Statistical analysis
Sample size and power calculations have been described 
previously (appendix pp 8–53).25,26 Briefly, we calculated 
that 149 participants per group were needed to provide 
92·6% power at the 5% significance level. Our target 
Standardised 
medical care (n=182)
CBT plus standardised 
medical care (n=186)
Total 
(n=368)
Age, years
Mean (SD) 37·7 (14·5) 37·3 (14·2) 37·5 (14·3)
Median (IQR; range) 35 (25–49; 18–77) 35 (25– 47; 18–78) 35 (25–48; 18–78)
Gender*
Female 126 (69%) 140 (75%) 266 (72%)
Male 56 (31%) 46 (25%) 102 (28%)
Ethnicity*
White 163 (90%) 167 (90%) 330 (90%)
Asian 4 (2%) 2 (1%) 6 (2%)
Black 1 (1%) 5 (3%) 6 (2%)
Mixed 9 (5%) 8 (4%) 17 (5%)
Other 5 (3%) 4 (2%) 9 (2%)
Relationship status
Single, separated, or widowed 85 (47%) 88 (47%) 173 (47%)
Married or living with partner 97 (53%) 98 (53%) 195 (53%)
Living with others 158 (87%) 158 (85%) 316 (86%)
Has dependants 57 (31%) 64 (34%) 121 (33%)
Has a carer 69 (38%) 80 (43%) 149 (40%)
Qualifications†
None 21/181 (12%) 22/186 (12%) 43/367 (12%)
Secondary 41/181 (23%) 48/186 (26%) 89/367 (24%)
Vocational 66/181 (36%) 54/186 (29%) 120/367 (33%)
Further (A-level or equivalent) 28/181 (15%) 28/186 (15%) 56/367 (15%)
Higher (BSc or equivalent and 
higher)
25/181 (14%) 34/186 (18%) 59/367 (16%)
Currently employed or in 
education*
58/180 (32%) 65/185 (35%) 123/365 (34%)
Receiving disability benefits if working age (<65 years)*
Yes (unemployed) 86/115 (75%) 79/118 (67%) 165/233 (71%)
Yes (employed) 13/58 (22%) 5/52 (10%) 18/110 (16%)
Dissociative seizures diagnosed by 
EEG and video*
94 (52%) 101 (54%) 195 (53%)
Age at first dissociative seizure, years*‡
Mean (SD) 30·9 (14·6) 31·0 (13·5) 30·9 (14·1)
Median (IQR; range) 29 (19–42; 5–76) 29 (19–41·5; 1–67) 29 (19–42; 1–76)
Duration of dissociative seizure symptoms, years*‡
Mean (SD) 6·5 (9·7) 5·9 (7·8) 6·2 (8·8)
Median (IQR; range) 3 (1–8; 0–65) 3 (1–7·5; 0–44) 3 (1–8; 0–65)
Predominant dissociative seizure type*
Hypokinetic 60/181 (33%) 70/185 (38%) 130/366 (36%)
Hyperkinetic 121/181 (67%) 115/185 (62%) 236/366 (64%)
Mean belief in diagnosis score 
(SD; range)*§
8·0 (2·2; 0–10) 8·0 (2·2; 0–10) 8·0 (2·2; 0–10)
Previous diagnosis of epilepsy 
(patient reported)
52 (29%) 49 (26%) 101 (27%)
Previous diagnosis of epilepsy* 
(doctor reported)
53 (29%) 36 (19%) 89 (24%)
Currently prescribed any anti-
epileptic drugs (patient reported)
36 (20%) 40 (22%) 76 (21%)
Ever sought medical help for a 
mental health problem
116 (64%) 125 (67%) 241 (65%)
Comorbid medical conditions 131/181 (72%) 130/184 (71%) 261/365 (72%)
(Table 1 continues on next page)
Articles
www.thelancet.com/psychiatry   Vol 7   June 2020 497
randomised controlled trial sample size was changed 
from 298 to 356 to accommodate lower than anticipated 
follow-up rates (appendix p 54).
The analyses followed the agreed statistical analysis 
plan,26 published before database lock. All analyses were 
done using Stata (version 15.0). Descriptive statistics 
summarising pre-randomisation variables and outcome 
measures at 6 and 12 months were reported by treatment 
group and overall.
Primary and secondary outcomes were assessed in the 
intention-to-treat population with multiple imputation 
used to facilitate the inclusion of all randomised 
participants in formal analyses. The effectiveness of CBT 
plus standardised medical care intervention was deter-
mined by assessing the between-group differences in 
primary or secondary outcome measures at 12 months.26 
To ensure that the trial statisticians remained unaware of 
treatment allocation for as long as possible, an inde-
pendent statistician determined that treatment com-
pliance within the intervention group (attendance at 
nine or more CBT sessions) was predictive of observed 
12-month primary outcome values (Fisher’s exact test 
p<0·001). Therefore, we used multiple imputation with 
100 impu tations to produce inferences that are valid 
under such a missing at random data-generating 
process.34 Multiple imputation requires the specification 
of an analysis and an imputation model; details of these 
models are provided in the appendix (pp 76–79). Briefly, 
for overdispersed count variables (seizure frequency and 
seizure freedom), both imputation and analysis models 
assumed a negative binomial distribution. For con-
tinuous and discrete outcome variables, such as seizure 
severity or bothersomeness, modelling was based on a 
normal distribution. Logistic regression models were 
used for binary outcomes. We report original inferences 
(p values or CIs were not corrected for multiple secondary 
outcome comparisons).
We did two sensitivity analyses. First, agreement 
between the two different methods of recording the 
primary outcome (diary or questionnaire item) was 
assessed by calculating an intraclass correlation coefficient 
on the log scale, and the sensitivity of the finding to the 
recording method was assessed by repeating the multiple 
imputation analysis after treating patients who did not 
provide the diary measure (considered the gold standard) 
as missing. Second, all 17 outcomes were re-analysed on a 
complete case basis (ie, without imputation or adjustment 
for baseline predictors of missingness). To assess the 
efficacy of CBT in the presence of non-compliance, the 
complier average causal effect (CACE) was estimated for 
the primary outcome; log-transformed seizure frequency 
was considered the dependent variable and treatment 
receipt as the explanatory variable and its effect estimated 
by a two-stage least squares estimator. Multiple imputation 
was used as described previously.
The trial was overseen by a Trial Management Group, 
Trial Steering Committee, and Data Monitoring and 
Ethics Committee. This trial is registered with Inter-
national Standard Randomised Controlled Trial registry, 
ISRCTN05681227, and ClinicalTrials.gov, NCT02325544.
Role of the funding source
The funder had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
The corresponding author had access to all study data 
and had final responsibility for the decision to submit for 
publication.
Results
Between Jan 16, 2015, and May 31, 2017, from the 
698 people who were intially recruited to the study,35 we 
randomly assigned 368 patients to standardised medical 
care alone (n=182) or CBT plus standardised medical 
care (n=186; figure 1). Recruitment by site is shown in 
the appendix (pp 55–57). Demographic data for the 
368 partici pants who participated in the trial and the 
58 patients who were eligible for the randomised 
controlled trial but could not be recruited are shown in 
the appendix (pp 58–59). No significant differences in key 
characteristics measured during the 3-month observation 
period were identified between the two groups.
Baseline characteristics were balanced between the 
treatment groups (table 1; appendix pp 60–61). Most 
participants were women, white, unemployed, living in 
areas of high deprivation, and had at least one comorbid 
psychiatric diagnosis (appendix pp 62–64) with a median 
of two current MINI diagnoses (range 0–8). 211 (58%) of 
363 patients had SAPAS-SR scores suggestive of 
maladaptive personality traits. Age at onset was variable 
(range 1–76 years) with a peak at 19 years (median 
29 years [IQR 19–42]). The range of the duration of the 
dissociative seizure disorder was also variable (range 
0–65 years) with a median duration of 3 years (IQR 1–8; 
table 1).
The demographic characteristics of the clinicians 
treating study participants, the number of standardised 
medical care sessions attended in both treatment groups, 
Standardised 
medical care (n=182)
CBT plus standardised 
medical care (n=186)
Total 
(n=368)
(Continued from previous page)
Screening tool for maladaptive personality traits (SAPAS-SR)
Mean (SD; range) 4·0 (2·0; 0–8) 3·9 (1·9; 0–8) 3·9 (2·0; 0–8)
Patients with ≥4 traits 108/181 (60%) 103/182 (57%) 211/363 (58%)
Any current DSM-IV diagnosis¶ 125 (69%) 130 (70%) 255 (69%)
Any previous DSM-IV diagnosis¶ 112 (62%) 135 (73%) 247 (67%)
Data are n (%) or n/N (%), unless otherwise specified. CBT=cognitive behavioural therapy. EEG=electroencephalogram. 
SAPAS-SR=Standardised Assessment of Personality Abbreviated Scale Self Report. *Recorded after consent was 
obtained for the 3-month screening period. †Qualifications based on UK educational system. ‡Data available for 
181 patients in the standardised medical care group and 184 patients in the CBT plus standardised medical care group. 
§Data available for 181 patients in the standardised medical care group and 185 patients in the CBT plus standardised 
medical care group. ¶Based on the Mini-International Neuropsychiatric Interview.
Table 1: Baseline demographic and clinical characteristics of the intention-to-treat population (n=368)
Articles
498 www.thelancet.com/psychiatry   Vol 7   June 2020
Baseline 6 months 12 months
Standardised 
medical care 
(n=182)
CBT plus 
standardised 
medical care 
(n=186)
Overall 
(n=368)
Standardised 
medical care 
(n=182)
CBT plus 
standardised 
medical care 
(n=186)
Overall 
(n=368)
Standardised 
medical care 
(n=182)
CBT plus 
standardised 
medical care 
(n=186)
Overall 
(n=368)
Monthly seizure frequency
Patients with available data, 
n (%)
182 (100%) 186 (100%) 368 (100%) 162 (89%) 161 (87%) 323 (88%) 157 (86%) 156 (84%) 313 (85%)
Median seizure frequency 
(IQR; range)
19 (5–49; 
0–649)
12·5 (4–41; 
0–535)
15 (4–47; 
0–649)
18 (3–48; 
0–640)
6 (0–24; 
0–849)
9 (1–38; 
0–849)
7 (1–35; 
0–994)
4 (0–20; 
0–571)
5 (0–27; 
0–994)
Seizure severity*
Patients with available data, 
n (%)
179 (98%) 182 (98%) 361 (98%) 135 (74%) 125 (67%) 260 (71%) 130 (71%) 129 (69%) 259 (70%)
Mean score (SD; range) 4·8 (1·6; 
1–7)
4·7 (1·6; 
1–7)
4·7 (1·6; 
1–7)
4·4 (1·6; 
1–7)
3·9 (1·9; 
1–7)
4·1 (1·8; 
1–7)
4·1 (1·8; 
1–7)
3·8 (1·8; 
1–7)
4·0 (1·8; 
1–7)
Seizure bothersomeness†
Patients with available data, 
n (%)
180 (99%) 182 (98%) 362 (98%) 143 (79%) 134 (72%) 277 (75%) 132 (73%) 131 (70%) 263 (71%)
Mean score (SD; range) 5·4 (1·7; 
1–7)
5·2 (1·7; 
1 –7)
5·3 (1·7; 
1–7)
4·7 (2·0; 
1–7)
3·9 (2·1; 
1–7)
4·3 (2·1; 
1–7)
4·6 (2·1; 
1–7)
3·9 (2·0; 
1–7)
4·2 (2·1; 
1–7)
Longest period of seizure freedom in past 6 months
Patients with available data, 
n (%)
181 (99%) 186 (100%) 367 (100%) NA NA NA 143 (79%) 140 (75%) 283 (77%)
Median number of seizure-free 
days* (IQR; range)
7 (2–21; 
0–84)
7 (2–21; 
0 –119)
7 (2–21; 
0–119)
NA NA NA 12 (3–42; 
0–343)
21 (5–97·5; 
0–357)
14 (3–70; 
0–357)
Seizure freedom in past 3 months
Patients with available data, 
n (%)
NA NA NA NA NA NA 145 (80%) 148 (80%) 293 (80%)
Yes, n (%) NA NA NA NA NA NA 18 (12%) 29 (20%) 47 (16%)
No, n (%) NA NA NA NA NA NA 127 (88%) 119 (80%) 246 (84%)
>50% reduction in monthly seizure frequency relative to baseline
Patients with available 
data, n (%)
NA NA NA 157 (86%) 153 (82%) 310 (84%) 152 (84%) 149 (80%) 301 (82%)
Yes, n (%) NA NA NA 43 (27%) 65 (42%) 108 (35%) 60 (39%) 68 (46%) 128 (43%)
No, n (%) NA NA NA 114 (73%) 88 (58%) 202 (65%) 92 (61%) 81 (54%) 173 (57%)
SF-12v2‡
Patients with available data, 
n (%)
181 (99%) 185 (99%) 366 (99%) 142 (78%) 134 (72%) 276 (75%) 145 (80%) 148 (80%) 293 (80%)
Mean Physical Component 
Summary score (SD; range)
38·8 (11·9; 
13·9–65·6)
40·5 (12·4; 
13·4–65·9)
39·7 (12·2; 
13·4–66·0)
38·8 (11·4; 
13·1–59·5)
41·5 (13·4; 
15·9–66·7)
40·1 (12·4; 
13·1–66·7)
38·0 (12·6; 
10·4–63·7)
41·5 (13·4; 
12·2–67·3)
39·8 (13·1; 
10·4–67·3)
Mean Mental Component 
Summary score (SD; range)
37·9 (11·4; 
16·9–68·1)
37·7 (12·2; 
13·4–67·6)
37·8 (11·8; 
13·4–68·1)
37·5 (12·1; 
10·5–63·0)
40·3 (11·7; 
17·4–67·5)
38·8 (12·0; 
10·5–67·5)
39·5 (11·8; 
11·3–62·9)
41·5 (12·8; 
13·9–65·7)
40·5 (12·4; 
11·3–65·7)
EQ-5D-5L visual analogue scale‡
Patients with available data, 
n (%)
181 (99%) 182 (98%) 363 (99%) 143 (79%) 135 (73%) 278 (76%) 145 (80%) 148 (80%) 293 (80%)
Mean score (SD; range) 54·9 (21·9; 
10–100)
56·2 (24·1; 
1–100)
55·5 (23·0; 
1–100)
50·9 (23·1; 
0–100)
58·8 (24·4; 
0–100)
54·7 (24·0; 
0–100)
53·4 (22·6; 
5–100)
61·1 (24·0; 
5–100)
57·3 (23·6; 
5–100)
WSAS
Patients with available data, 
n (%)
181 (99%) 185 (99%) 366 (99%) 143 (79%) 135 (73%) 278 (76%) 145 (80%) 148 (80%) 293 (80%)
Mean score§ (SD; range) 22·9 (10·5; 
0–40)
22·5 (10·5; 
0–40)
22·7 (10·5; 
0–40)
22·7 (11·9; 
0–40)
17·8 (13·1; 
0–40)
20·3 (12·7; 
0–40)
21·1 (12·7; 
0–40)
16·4 (13·1; 
0–40)
18·7 (13·1; 
0–40)
GAD-7 scale
Patients with available data, 
n (%)
182 (100%) 186 (100%) 368 (100%) 143 (79%) 135 (73%) 278 (76%) 145 (80%) 148 (80%) 293 (80%)
Mean score¶ (SD; range) 10·0 (6·2; 
0–21)
9·6 (6·2; 
0–21)
9·8 (6·2; 
0–21)
10·5 (6·3; 
0–21)
8·1 (6·5; 
0–21)
9·4 (6·5; 
0–21)
9·3 (6·1; 
0–21)
8·2 (6·0; 
0–21)
8·8 (6·1; 
0–21)
(Table 2 continues on next page)
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and the number of CBT sessions attended are shown in 
the appendix (pp 65–69). The number of standardised 
medical care appointments offered and attended were 
similar across treatment groups. One patient allocated to 
standardised medical care alone received our dissociative 
seizure-specific CBT in error. 104 (56%) of 186 participants 
in the CBT plus standardised medical care group 
attended all 12 CBT sessions (plus the booster session) 
and 140 (75%) of 186 patients were compliant according 
to our criterion26 (attending nine sessions or more). 
The median time between random isation and first 
CBT session was 38·5 days (IQR 26–59). Ten (5%) of 
186 patients formally withdrew from CBT. Therapists’ 
ratings of patients’ acceptance of the therapy model and 
adherence to treatment between sessions are shown in 
the appendix (pp 68–69). Therapy fidelity ratings for the 
36 rated sessions across the rated categories show good 
therapeutic alliance, adherence to the therapy manual, 
and delivery of CBT (appendix p 70).
Primary outcome data were available for 313 (85%) of 
368 patients: 157 (86%) of 182 patients in the standardised 
medical care group alone versus 156 (84%) of 186 in the 
CBT plus standardised medical care group. No study 
withdrawals or losses to follow-up were deemed to be 
associated with reported adverse events or death.
Primary and secondary outcome measures at all 
timepoints are summarised in table 2. For the primary 
outcome, no significant differences in monthly dis-
sociative seizure frequency were identified between the 
groups at 12 months (median 4 seizures [IQR 0–20] 
in the CBT plus standardised medical care group 
vs 7 seizures [1–35] in the standardised medical care 
group; estimated incidence rate ratio [IRR] 0·78 [95% CI 
0·56–1·09]; p=0·144; table 3, figure 2). Although 
Baseline 6 months 12 months
Standardised 
medical care 
(n=182)
CBT plus 
standardised 
medical care 
(n=186)
Overall 
(n=368)
Standardised 
medical care 
(n=182)
CBT plus 
standardised 
medical care 
(n=186)
Overall 
(n=368)
Standardised 
medical care 
(n=182)
CBT plus 
standardised 
medical care 
(n=186)
Overall 
(n=368)
(Continued from previous page)
PHQ-9
Patients with available data, 
n (%)
181 (99%) 186 (100%) 367 (100%) 142 (78%) 135 (73%) 277 (75%) 145 (80%) 148 (80%) 293 (80%)
Mean score|| (SD; range) 12·6 (6·5; 
0–26)
12·3 (6·7; 
0–27)
12·4 (6·6; 
0–27)
12·9 (7·0; 
0–27)
11·2 (7·4; 
0–27)
12·1 (7·2; 
0–27)
11·7 (6·7; 
0–26)
10·5 (7·5; 
0–26)
11·1 (7·1; 
0–26)
CORE-10
Patients with available data, 
n (%)
182 (100%) 186 (100%) 368 (100%) 142 (78%) 135 (73%) 277 (75%) 145 (80%) 148 (80%) 293 (80%)
Mean score§ (SD; range) 18·2 (6·3; 
4–34)
18·2 (6·7; 
4–32)
18·2 (6·5; 
4–34)
18·6 (6·6; 
2–34)
17·2 (7·1; 
0–39)
17·9 (6·9; 
0–39)
18·1 (6·6; 
3–33)
16·6 (6·8; 
1–38)
17·3 (6·7; 
1–38)
Modified PHQ-15
Patients with available data, 
n (%)
181 (99%) 183 (98%) 364 (99%) 140 (77%) 135 (73%) 275 (75%) 145 (80%) 147 (79%) 292 (79%)
Mean score** (SD; range) 16·7 (6·2; 
2–30)
16·7 (6·8; 
2–30)
16·7 (6·5; 
2–30)
16·8 (6·7; 
0–29)
14·9 (7·4; 
0–28)
15·9 (7·1; 
0–29)
15·9 (6·9; 
0–29)
14·1 (7·7; 
0–28)
15·0 (7·4; 
0–29)
Clinical global impression of improvement††
Patients with available data, 
n (%)
NA NA NA 140 (77%) 135 (73%) 275 (75%) 145 (80%) 148 (80%) 293 (80%)
Mean self-reported change 
score (SD; range)
NA NA NA 3·4 (1·6; 
0–6)
4·2 (1·3; 
0–6)
3·8 (1·5; 
0–6)
3·6 (1·8; 
0–6)
4·3 (1·5; 
0–6)
4·0 (1·7; 
0–6)
Patients with available data, 
n (%)
NA NA NA NA NA NA 162 (89%) 161 (87%) 323 (88%)
Mean clinician-rated change 
score (SD; range)
NA NA NA NA NA NA 3·8 (1·3; 
0–6)
4·4 (1·2; 
0–6)
4·1 (1·3; 
0–6)
Patient satisfaction with treatment‡‡
Patients with available data, 
n (%)
NA NA NA 140 (77%) 135 (73%) 275 (75%) 145 (80%) 148 (80%) 293 (80%)
Mean satisfaction score (SD; 
range)
NA NA NA 3·8 (2·0; 
0–6)
5·1 (1·3; 
0–6)
4·4 (1·8; 
0–6)
4·2 (2·0; 
0–6)
5·2 (1·4; 
0–6)
4·7 (1·8; 
0–6)
CBT=cognitive behavioural therapy. SF-12v2=12-item Short Form 12 Survey–version 2. EQ-5D-5L=EuroQoL-5 Dimensions-5 Level scale. WSAS=Work and Social Adjustment Scale. GAD-7=Generalised Anxiety 
Disorder seven-item. PHQ-9=Patient Health Questionnaire nine-item. CORE-10=Clinical Outcomes in Routine Evaluation-10. PHQ-15=Patient Health Questionnaire fifteen-item. *Measured on a 7-point scale 
(1=very mild; 7=very severe). †Measured on a 7-point scale (1=no bother at all; 7=very bothersome). ‡Measured on a 100 point scale (0=worst health; 100=best health). §Possible range 0–40. ¶Possible range 
0–21. ||Possible range 0–27. **Possible range 0–30. ††Change scores measured on a 7-point scale (0=very much worse; 6=very much better). ‡‡Measured on a 7-point scale (0=very dissatisfied; 6=very satisfied).
Table 2: Descriptive summaries of primary and secondary outcome measures
Articles
500 www.thelancet.com/psychiatry   Vol 7   June 2020
dissociative seizure frequency seemed to decrease with 
time in both groups, dissociative seizure frequency 
seemed to decrease at an earlier timepoint in the CBT 
plus standardised medical care group than in the 
standardised medical care group (table 2, figure 2). At 
12 months, participants in the CBT plus standardised 
medical care group rated their seizures as less bother-
some than the standardised medical care group (estimated 
mean difference –0·53 [95% CI –0·97 to –0·08]; p=0·020), 
but no significant differences were identified in patient-
reported seizure severity between the groups (p=0·593; 
table 3). No significant differences were identified in the 
proportion of patients with seizure freedom in the last 
3 months of the study (p=0·083) or the proportion of 
patients who had a more than 50% reduction in 
dissociative seizure frequency between the two groups 
(p=0·313); however, at 12 months participants in the 
CBT plus standardised medical care group had nearly 
two-thirds longer periods of seizure freedom in the 
previous 6 months than did patients in the standardised 
medical care group (IRR 1·64 [95% CI 1·22–2·20; 
p=0·001; table 3). Only 27 carers or others nominated by 
patients provided a rating of changes in the patients’ 
seizures; thus, this outcome could not be analysed.
The SF-12v2 Physical Component Summary and 
Mental Component Summary measures of health-related 
quality of life did not significantly differ between groups 
at 12 months (p=0·105 and p=0·084, respectively; table 3). 
However, the CBT plus standardised medical care group 
reported a better health rating on the EQ-5D-5L visual 
analogue scale than did the standardised medical care 
group (estimated mean difference 6·16 [95% CI 1·48 to 
10·84]; p=0·010; table 3).
Psychosocial functioning (measured by WSAS) was 
significantly better in the CBT plus standardised medical 
care group than the standardised medical care group at 
12 months (estimated mean difference –4·12 [95% CI 
–6·35 to –1·89]; p<0·001; table 3). No significant differ-
ences in anxiety (p=0·069) and depression (p=0·099) 
scores were identified between the groups at 12 months 
(table 3); however, the more general measure of psycho-
logical distress (CORE-10) showed better psycho logical 
functioning in the CBT plus stan dardised medical 
care group than the standardised medical care group 
(estimated mean difference –1·65 [95% CI –2·96 to 
–0·35]; p=0·013; table 3). The CBT plus standardised 
medical care group reported fewer somatic symptoms, as 
measured by the modified PHQ-15, than the standardised 
medical care group (estimated mean difference –1·67 
[95% CI –2·90 to –0·44]; p=0·008) (table 3).
The CBT plus standardised medical care group self-
reported greater clinical improvement than did the 
standardised medical care group (estimated mean 
difference 0·66 [95% CI 0·26 to 1·04; p=0·001; table 3) 
with a similar pattern observed for the standardised 
medical care clinicians’ ratings of patients’ improvement 
(estimated mean difference 0·47 [95% CI 0·21 to 0·73]; 
p<0·001; table 3). Raw data plots to illustrate observed 
changes in all secondary outcomes over time and by 
treatment group are shown in the appendix (pp 83–90).
 The CBT plus standardised medical care group also 
reported greater satisfaction with treatment than the 
standardised medical care group (estimated mean 
difference 0·90 [95% CI 0·48 to 1·31; p<0·001; table 3; 
appendix p 71).
The size of the standardised treatment effects for all 
secondary outcomes analysed on a continuous scale are 
shown in figure 3. For table 3 outcomes that were inter-
preted as being in favour of CBT plus standardised 
medical care if the standardised group difference was 
less than 0, the estimated effect was reflected (ie, 
multiplied by –1) in figure 3 so that outcomes for which 
the standardised group difference was higher than 0 
could be interpreted as being in favour of the intervention.
The p values in table 3 have not been adjusted for 
multiple testing.26 Considering conser vative adjustment 
Estimated mean 
difference* (95% CI)
Standardised group 
difference (95% CI)
p value
Primary outcome
Monthly seizure frequency in last 
4 weeks
NA 0·78 (0·56 to 1·09)† 0·144
Secondary outcomes
Seizure severity score –0·11 (–0·50 to 0·29) –0·07 (–0·31 to 0·18) 0·593
Seizure bothersomeness severity 
score
–0·53 (–0·97 to –0·08) –0·30 (–0·56 to –0·05) 0·020‡
Longest period of seizure freedom 
in past 6 months (days)
NA 1·64 (1·22 to 2·20)† 0·001†
Seizure freedom in last 3 months of 
trial
NA 1·77 (0·93 to 3·37)§ 0·083
>50% reduction in monthly seizure 
frequency relative to baseline
NA 1·27 (0·80 to 2·02)§ 0·313
Physical Component Summary 
score (SF-12v2)
1·78 (–0·37 to 3·92) 0·15 (–0·03 to 0·32) 0·105
Mental Component Summary score 
(SF-12v2)
2·22 (–0·30 to 4·75) 0·15 (–0·03 to 0·33) 0·084
EQ-5D-5L visual analogue scale 6·16 (1·48 to 10·84) 0·27 (0·06 to 0·47) 0·010†
Impact on functioning (WSAS) –4·12 (–6·35 to –1·89) –0·39 (–0·61 to –0·18) <0·001†
Anxiety (GAD-7) –1·09 (–2·27 to 0·09) –0·18 (–0·37 to 0·01) 0·069
Depression (PHQ-9) –1·10 (–2·41 to 0·21) –0·17 (–0·37 to 0·03) 0·099
Distress (CORE-10) –1·65 (–2·96 to –0·35) –0·25 (–0·45 to –0·05) 0·013‡
Other somatic symptoms 
(modified PHQ-15)
–1·67 (–2·90 to –0·44) –0·26 (–0·45 to –0·07) 0·008‡
Self-reported change (CGI score) 0·66 (0·26 to 1·04) 0·39 (0·16 to 0·62) 0·001‡
Clinician-rated change (CGI score) 0·47 (0·21 to 0·73) 0·37 (0·17 to 0·57) <0·001‡
Patient-reported satisfaction with 
treatment
0·90 (0·48 to 1·31) 0·50 (0·27 to 0·73) <0·001‡
p values not adjusted for multiple testing. Standardised group differences between 0·35 and 0·65 were considered 
moderate. NA=not applicable. SF-12v2=12-item Short Form survey–version 2. EQ-5D-5L=EuroQoL-5 Dimensions-5 
Level scale. WSAS=Work and Social Adjustment Scale. GAD-7=Generalised Anxiety Disorder seven-item. 
PHQ-9=Patient Health Questionnaire nine-item. CORE-10=Clinical Outcomes in Routine Evaluation-10. 
PHQ-15=Patient Health Questionnaire fifteen-item. CGI=Clinical Global Impression. *Using original scales.†Treatment 
effects for count outcomes are presented as incidence rate ratios. ‡Statistically significant at 5% level (not accounting 
for multiple testing). §Treatment effects for binary outcomes are presented as odds ratios.
Table 3: Comparison of outcome measures between the CBT plus standardised medical care and 
standardised medical care alone groups at 12 months derived by multiple imputation (100 imputations)
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(eg, post-hoc Bonferroni cor rection of 0·05/17=0·003), 
five secondary outcomes suggest that CBT plus 
standardised medical care provided significant benefit 
to participants compared with standardised medical 
care: longest period of seizure freedom, psychosocial 
functioning, self-rated and clinician-rated global change, 
and treatment satisfaction (table 3).
CBT therapists rated 82 (54%) of 152 patients who 
received CBT as much better or very much better at the 
end of treatment (appendix p 71).
Sensitivity analyses showed high agreement between 
the questionnaire and diary records (intraclass corre-
lation coefficient=0·95); exclusion of 21 participants 
without diary data at 12 months resulted in the same 
finding for the primary outcome (IRR 0·74 [95% CI 
0·53–1·04]; p=0·086). Complete case analyses of the 
primary and secondary outcomes are shown in the 
appendix (p 72). Comparison with table 3 showed that 
use of multiple imputation to adjust for missing data 
had little effect on the results, with similar findings for 
the primary outcome and the secondary outcomes. 
CACE analysis modelled the effect of receiving the 
intervention (at least nine sessions of CBT) and 
estimated the efficacy of the intervention, rather than its 
effective ness (estimated by ITT analysis). We found the 
efficacy of receiving CBT was estimated to be the same 
as the effectiveness of being offered CBT (IRR 0·78, 
95% CI 0·53–1·16; p=0·217).
During the entire 12-month follow-up period, 
110 participants had 176 adverse events: 57 (31%) of 
186 participants in the CBT plus standardised medical 
care group reported 97 adverse events and 53 (29%) of 
182 participants in the stan dardised medical care group 
reported 79 adverse events. Psychological events were 
the most common type of adverse event in the CBT plus 
standardised medical care group (n=24), which included 
deteriorations in mood and musculoskeletal events 
were the most common type of adverse event reported 
in the standardised medical care group (n=17), such as 
reports of injuries from dissociative seizures. All serious 
adverse events and adverse events are shown in the 
appendix (pp 73–74). No adverse events or serious 
adverse events were deemed to be associated with the 
CBT plus standardised medical care intervention by our 
independent raters. The incidence of serious adverse 
events was similar across both groups (24 [13%] of 
182 participants in the standardised medical care alone 
group vs 25 [13%] of 186 patients in the CBT plus 
standardised medical care group; table 4). Considering 
other potential indices of harm, only one patient had a 
decline of at least 20 points (2 SD) on the SF-12v2 
Physical Component Summary. At 12 months, on the 
Clinical Global Impression scale, 25 (17%) of 145 patients 
in the standardised medical care group and 13 (9%) of 
148 patients in the CBT plus standardised medical 
care group self-reported being much worse or very 
much worse.
Discussion
To our knowledge, this is the largest randomised 
controlled trial that has been done to date, assessing a 
psychotherapeutic intervention for adults with disso-
ciative seizures, in the context of a care pathway involving 
both neurology and psychiatry services. Our analysis 
showed that at 12 months after randomisation no 
significant differences in dissociative seizure frequency 
were observed between the CBT plus standardised 
medical care and standardised medical care groups. For 
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Figure 2: Changes in geometric mean seizure frequency over time
Raw data plot of geometric mean seizure frequency in the past 4 weeks. Baseline 
seizure frequency was recorded before randomisation. The primary outcome was 
measured at 12 months; 6-month measures were not formally assessed in this 
study, but are included here to illustrate observed data. Error bars show 95% CIs. 
CBT=cognitive behavioural therapy.
Figure 3: Standardised group differences for all secondary outcomes analysed on a continuous scale
Forest plot of standardised group differences between CBT plus standardised medical care and standardised 
medical care groups for all 13 continuous secondary outcomes, whereby a standardised treatment effect higher 
than 0 favoured the CBT plus standardised medical care group. Error bars show 95% CIs. CBT=cognitive 
behavioural therapy. SF-12v2=12-item Short Form 12 Survey–version 2. EQ-5D-5L=EuroQoL-5 Dimensions-5 
Levels scale. VAS=visual analogue scale. WSAS=Work and Social Adjustment Scale. GAD-7=Generalised Anxiety 
Disorder-7 scale. PHQ-9=Patient Health Questionnaire-9 scale. CORE-10=Clinical Outcomes in Routine 
Evaluation-10. PHQ-15=Patient Health Questionnaire-15 scale. CGI=Clinical Global Impression.
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nine of 16 secondary outcome measures, between-group 
differences were significant at the unadjusted 5% level 
(p≤0·05). These data suggest that compared with stan-
dardised medical care alone, CBT plus standardised 
medical care provided particular benefits with regard 
to the longest period of seizure freedom at 12 months, 
psychosocial functioning, self-rated and clinician-rated 
global change, and treatment satisfaction and all showed 
standardised group differences in the moderate range. 
Treatment compliance among patients in the intervention 
group was high (75%) and therapists showed good 
adherence to the therapy manual, and were found to be 
delivering CBT as intended.
By contrast with our earlier study,23 this trial suggests 
that dissociative seizure-specific CBT could contribute to 
improvement in clinically important aspects of psycho-
social functioning and perceptions of health among 
patients with dissociative seizures. These improve ments 
were observed despite the observation that at baseline 
more than half of the cohort self-reported maladaptive 
personality traits, more than two-thirds had at least one 
other comorbid mental health disorder, and participants 
did not enter the study until dissociative seizures had 
already been present for a median of 3 years. Before 
treatment, the cohort also had below average health-related 
quality-of-life scores on the SF-12v2.36 Patients also reported 
mean scores on the WSAS consistent with at least 
moderately severe functional impairment when sum-
marising across the domains of work, home management, 
social and private leisure activities, and the ability to form 
and maintain interpersonal relationships.37 Furthermore, 
self-rated health on the EQ-5D-5L visual analogue scale 
was scored considerably below the national average.38 
Increasing evidence suggests that seizure frequency alone 
is not the most important determinant of quality of life in 
patients with dissociative seizures. A 2017 study39 found 
that mood, anxiety, and illness perceptions were the factors 
most closely linked with quality of life in patients with 
dissociative seizures, emphasising the importance of the 
secondary outcome effects in this trial. These effects are 
particularly notable since therapists might have faced 
additional challenges because patients were not 
preselected by therapists for their suitability for a 
cognitive behavioural intervention, which might be the 
case in routine service delivery.
A wider issue raised in this study is that of best practice 
for treatment trials of dissociative seizures. This study 
followed a standard clinical trial approach of offering a 
specific intervention to a patient group and measuring 
outcomes. However, particular subgroups of patients 
might be more likely to respond to a CBT-based treatment, 
and others more likely to respond to other psycho-
therapeutic or pharmacological interventions. This idea is 
commonly applied in clinical practice—eg, a specific 
patient might be deemed unlikely to engage meaningfully 
with a psychotherapeutic intervention, even if that 
intervention is generally regarded as a treatment of choice 
for the condition in question. These are judgements that 
rely on clinical impression but to base such decisions on 
empirical evidence would require formal trials of 
treatment regimens tailored to subgroups of patients. 
Similar comments could be made regarding treatment 
studies of many other conditions, particularly those that 
involve a complex interplay of psychological and physical 
factors that might vary considerably between individuals, 
even if their symptoms are similar. However, it might be 
possible to identify factors that make individuals more 
likely to respond to particular inter ventions. This issue is 
outside the scope of this Article, but we hope to explore it 
further in subsequent statistical analysis of the impact of 
moderating and mediating variables on treatment 
outcomes in this trial, which will be reported separately.
Regarding study limitations, we did not include a 
waiting list or treatment-as-usual control group and, 
thus, are unable to determine whether the apparent 
reduction in dissociative seizure frequency observed in 
both groups at 12 months represents equal effectiveness 
of the treatment allocations or the natural progression 
of the disorder in our sample. We are not aware of data 
on dissociative seizure outcome with no intervention 
over 12 months with which to compare our findings, 
although an uncontrolled retrospective study done over 
a longer period of time, without a psychological 
intervention, in a different cultural context, suggests 
that more than 50% of patients with dissociative 
seizures might become seizure free in the absence of 
psychotherapy,9 but it is not clear how quickly such 
improvement occurs. The control condition in this 
study might have been an active therapeutic intervention 
and, with the materials provided for patients and 
guidance given to clinicians about diagnosis delivery 
and management, might be better conceptualised as 
standardised specialist care than standardised medical 
care (appendix p 82).
Regarding other study limitations, our randomised 
controlled trial included a cohort who were selected using 
several inclusion criteria. Only individuals who were 
initially recruited after diagnosis by neurologists or 
epilepsy specialists and attended their psychiatric 
assessment could enrol. We excluded people with active 
epilepsy (ie, epileptic seizures in the previous 12 months) 
but acknowledge that where we relied on self-report for 
Standardised medical care 
(n=182)
CBT plus standardised medical 
care (n=186)
Events Participants Events Participants
Self-harm or suicidal ideation 6 6 (3%) 12 9 (5%)
Related to dissociative seizures 6 6 (3%) 5 5 (3%)
Other 15 14 (8%) 14 14 (8%)
Total 27 24 (13%) 31 25 (13%)
Data are n or n (%). CBT=cognitive behavioural therapy.
Table 4: Serious adverse events
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this criterion, this could potentially have led to the 
inclusion of some people with active seizures40 despite 
careful consensus review and the possibility of further 
review at the time of the psychiatric assessment. We 
restricted our sample to people without documented 
intellectual disabilities and without concurrent comorbid 
epileptic seizures to make evaluation of the individualised 
CBT more interpretable. Due to the uncertainty of being 
able to provide interpreters, only patients with sufficient 
English proficiency to enable completion of therapy and 
questionnaires without an interpreter were included. 
Consistent with usual clinical practice in the UK, 
diagnoses of dissociative seizures in our sample were 
supported by video-EEG recordings of typical dissociative 
seizure events in about half of all participants.19 In line 
with previous international expert recommendations,41 
and to ensure that the findings of the study were more 
readily generalisable to routine UK practice, we also 
sought to include patients for whom diagnosis had been 
reached without video-EEG confirmation. The risk of 
misdiagnosis, if clinical consensus had not already been 
obtained, was reduced in these cases by seeking expert 
review of the clinical records and relevant inves tigations 
and exclusion of patients with questionable diagnoses, 
although we did not classify levels of diagnostic certainty.41 
Video-EEG confirmation was not compulsory in this 
pragmatic trial since this diagnostic method is not 
available or cost-effective for many in routine clinical use, 
and treatment might be appropriately started at less than 
optimum levels of diagnostic certainty.41
Although randomisation would be expected to have led 
to similar baseline levels of psychotropic medication use 
in the two trial groups, we did not record the prescription 
of antidepressant and other psychotropic medication in 
the two treatment groups and cannot be sure that the 
standardised medical care alone group did not receive 
more of this type of treatment as a substitute for 
psychotherapeutic input than the CBT plus standardised 
medical care group; this is unfortunate considering the 
interest in the use of antidepressants for dissociative 
seizures either alone or in combination with CBT-
informed psychotherapy.24
Both groups were contacted frequently by researchers 
and were required to complete seizure diaries throughout 
the study, which might have acted as an intervention, not 
typically available in the NHS. Both patients and their 
treating doctors were aware of treatment allocation. 
Although doctors might have altered their practice 
depending on treatment allocation, patients received a 
similar number of standardised medical care sessions in 
the two groups. We did not, however, control for therapist 
time and attention. Although many patients will have 
come to the study with trauma histories, and the CBT 
intervention did address trauma, this was not specifically 
a trauma-focused therapy. We acknowledge that at the 
end of the study additional therapy might have been 
considered useful for some.
Although dissociative seizure frequency was our primary 
outcome, the usefulness of this as an outcome has been 
questioned.42 Recording this outcome con sistently in a 
large sample poses difficulties (appendix pp 75–76). 
Functional status might be a more meaningful outcome, 
especially if it occurs in the context of better ability to 
tolerate persistent dissociative seizures, enabling better 
everyday activity. We also note that it is unfortunate that 
non-adherence with CBT was predictive of missing 
outcome data but, wherever possible, unless individuals 
formally withdrew from the trial, we encouraged follow-up 
irrespective of treatment experience, but we could not 
insist that people provide outcome data when they 
discontinued attending CBT; however, the proportion of 
patients who provided outcome data was balanced between 
treatment groups.
The strengths of this study include the pragmatic 
design, large sample size, high follow-up rates, outcome 
assessments (other than clinician ratings) done by a 
masked researcher, and the large number of centres and 
therapists involved, which removed potential bias 
occurring in smaller study designs. The good compliance 
with CBT suggests that this approach would be acceptable 
for implementation in routine clinical use with appropriate 
training and supervision. During the 12 month follow-up 
period, no differences in adverse events or serious adverse 
events or other harms were identified between the CBT 
plus standardised medical care and standardised medical 
care groups.
In conclusion, our model of CBT was not shown to 
confer a benefit for dissociative seizure frequency at 
12 months when combined with specialist medical care 
involving careful explanation of the diagnosis and 
psychiatric care. Dissociative seizure-specific CBT was, 
however, associated with improvements in other secon-
dary clinical outcome measures including psychosocial 
functioning, and our results indicate that dissociative 
seizure-specific CBT can be delivered safely to a wide 
range of patients with dissociative seizures.
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